Artrya Limited (AYA.AX) Stock Analysis & Winston Score

Artrya Limited is an Australian medical technology company that uses artificial intelligence to help doctors analyze heart scans. Its main product, Salix, examines CT scans of coronary arteries — the blood vessels around the heart — and helps cardiologists spot blockages or disease faster than traditional manual review. The company sells its software to hospitals and cardiac imaging centers, primarily in Australia. Artrya makes money by licensing its AI software to healthcare providers, typically through subscription or per-scan fee arrangements. The company is small, with a market capitalization of around $500 million, and is still in an early commercial stage, which explains why its margins are deeply negative — it is spending far more than it earns right now. Regulatory approvals in larger markets like the United States would be a significant growth driver, but the main risk is that the company may need to raise additional capital before it reaches profitability.